Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"
- PMID: 31187470
- PMCID: PMC6584249
- DOI: 10.1007/s40262-019-00786-w
Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"
Conflict of interest statement
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran and Pierre-Louis Toutain have no conflicts of interest that are directly relevant to the content of this reply.
Comment on
-
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3. Clin Pharmacokinet. 2019. PMID: 30949873 Free PMC article.
-
Comment on "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?".Clin Pharmacokinet. 2019 Jul;58(7):969-971. doi: 10.1007/s40262-019-00785-x. Clin Pharmacokinet. 2019. PMID: 31187469 Free PMC article. No abstract available.
References
-
- Anonymous. Guideline on the investigation of bioequivalence (EMA, London, 2010). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin.... Accessed 20 May 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources